All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
12 warning events since 2017; the latest 2026-08-07.
From the record
HeartSciences Inc.'s filings since 2017 show 12 warning events: a notice about its exchange listing (8-K item 3.01, 12 times, the latest 2026-08-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-26% a year over 5 filed years; profitable in 0 of 5.
From the record
HeartSciences Inc.'s 5 filed years say what it did: revenue went from $14 thousand in fiscal 2022 to $4 thousand in fiscal 2026, down 26% a year; it rose in 1 of 4 years; the deepest fall was 77% from fiscal 2024 to fiscal 2026; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.5/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: HeartSciences Inc.'s shareholder treatment is put at 6.5 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 18 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
SI estimate 4.7/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: HeartSciences Inc.'s financial health is put at 4.7 of 10 with a confidence of 20 of 100, because fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 28 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How strong is its position in its industry?
bottom 4% of 26 in its family; net margin -211666.5%.
From the record
HeartSciences Inc.'s standing among 26 graded names in its industry family: revenue of $4 thousand in fiscal 2026 ranks in the bottom 2% by size; a net margin of -211666.5% ranks in the bottom 2%; revenue growth of -5.7% a year over the last 3 filed years ranks in the bottom 9% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 1.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: HeartSciences Inc.'s leadership is put at 1.1 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 11% of 23 in its family; the record of its people begins on 2022-07-06 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 4.4 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 6.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: HeartSciences Inc.'s room to expand is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 31% of 27 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 44% of 25 in its family for growth drivers.
From the record
HeartSciences Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew -5.7% a year over the last three filed years against -26% over all 5, speeding up (top 10% of its family); the newest year grew -0.7% (bottom 18%); research spending grew 4.9% a year (top 44%); capital spending grew -42.1% a year (bottom 10%) (its annual reports). HeartSciences Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 37% of 23 in its family for expectations against reality.
From the record
HeartSciences Inc.'s newest year against its own record: revenue of $4 thousand in fiscal 2026 came in 8% above the $4 thousand its prior three years' pace pointed to (top 23% of its family); net income of $9 million against a prior three-year average of $7 million (bottom 33%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 2%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made